In the PANGEA phase II trial [153], a personalized treatment strategy was applied in gastric cancer patients: antibodies targeting HER2, MET, FGFR2 EGFR PD-L1 or VEGFR2 were added to chemotherapy in first- to third-line treatment in gastric or GEJ cancer patients. This evidence concerns the gene ERBB2 and gastric cancer.